Examkin

Soru

Zorluk: OrtaPharmacologic Interventions

An infectious diseases consultation is requested for a 34-year-old male inpatient who has been experiencing progressive dyspnea, dry cough, and subjective fevers over the past three weeks. His past medical history is notable for an HIV diagnosis five years prior; however, he abandoned antiretroviral therapy two years ago. Vital signs reveal a temperature of 38.4∘C38.4^\circ\text{C} (101.1∘F101.1^\circ\text{F}), blood pressure of 112/70 mmHg, heart rate of 110/min, and respiratory rate of 24/min. Pulse oximetry demonstrates an oxygen saturation of 88%88\% while breathing ambient air, and a subsequent arterial blood gas analysis confirms a PaO2\text{PaO}_2 of 65 mmHg. Chest radiography displays bilateral, fine interstitial infiltrates. Microscopic examination of induced sputum using direct fluorescent antibody testing definitively identifies *Pneumocystis jirovecii*.

Which of the following pharmacologic interventions should be ordered immediately for this patient? (Select all that apply)

  1. Intravenous trimethoprim-sulfamethoxazoleCevap
  2. B
    Intravenous fluconazole
  3. Oral prednisoneCevap
  4. D
    Inhaled pentamidine
  5. E
    Oral leucovorin

Cevap

The correct interventions to order immediately are intravenous trimethoprim-sulfamethoxazole and oral prednisone.
The patient has severe Pneumocystis jirovecii pneumonia (PCP), as indicated by the positive sputum direct fluorescent antibody testing and significant hypoxemia. Intravenous trimethoprim-sulfamethoxazole is the standard first-line antimicrobial therapy for moderate-to-severe PCP. Furthermore, because the patient has a PaO2\text{PaO}_2 of less than 70 mmHg (specifically 65 mmHg in this scenario), adjunctive corticosteroids such as oral prednisone or intravenous methylprednisolone are strictly required. Corticosteroids critically reduce the severe inflammatory response triggered in the lungs by the rapid lysis of fungal organisms, significantly decreasing the risk of subsequent respiratory failure and mortality.

Adım Adım Çözüm

1
Assess the severity of the opportunistic infection.
The patient's PaO2\text{PaO}_2 is 65 mmHg on room air.
A PaO2<70\text{PaO}_2 < 70 mmHg or an A-a\text{A-a} gradient ≥35\geq 35 mmHg defines moderate-to-severe PCP, which alters the standard treatment protocol by requiring adjunctive therapy.
2
Select the primary antimicrobial agent.
Intravenous trimethoprim-sulfamethoxazole is chosen.
It remains the standard, most effective first-line targeted therapy for active Pneumocystis jirovecii pneumonia.
3
Identify the critical need for adjunctive pharmacotherapy based on severity parameters.
Oral prednisone (or intravenous methylprednisolone) is added to the regimen.
Adjuvant corticosteroids prevent rapid clinical deterioration caused by the intense inflammatory response triggered by dying PCP organisms in already hypoxic patients.

Anahtar Kavram

Patients with moderate-to-severe Pneumocystis jirovecii pneumonia, defined by a PaO2 < 70 mmHg or an A-a gradient >= 35 mmHg, must receive both targeted antimicrobial therapy (trimethoprim-sulfamethoxazole) and adjunctive corticosteroids.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Pharmacologic Interventions

Bu konudan daha fazla soru